In this context, we opine that treatment with HDAC3 (Sirt3) inhibitor might help mitigate early alveolar epithelial, and pulmonary capillary endothelial barriers disruption, and that may help preserve the blood-lung-barrier (BLB) functioning, and subsequently, that might help prevent leakage, and pulmonary edema/congestion in DMD patients [43,44,45,46]. Here, HDAC3 is linked to Duchenne muscular dystrophy.